Delamanid

Delamanid shares cardiac, hepatic, and neurologic signal profiles with bedaquiline. Delamanid is preferred over bedaquiline for patients with hepatitis C or antiretroviral therapy because of lower hepatotoxic potential and fewer drug interactions. Delamanid produces metabolite DM-6705, which contributes to QT prolongation through hERG potassium channel inhibition. Delamanid's label explicitly lists dyspnoea, supraventricular extrasystoles, and fever as adverse events. Delamanid most distinctively signaled decreased haemoglobin across all three analytical contexts.